[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342791-105":59,"doc-detail-342791-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","esophageal-cancer-outcomes-after-definitive-chemotherapy-with-intensity-modulated-proton-therapy","Esophageal Cancer Outcomes After Definitive Chemotherapy With Intensity Modulated Proton Therapy","","Effectiveness of intensity-modulated proton therapy (IMPT) for esophageal cancer treated with definitive concurrent chemoradiation remains insufficiently characterized. A retrospective cohort study analyzed 34 patients with locally advanced esophageal cancer receiving IMPT with concurrent chemotherapy at The University of Texas MD Anderson Cancer Center between 2011 and 2021. Kaplan-Meier methods assessed survival, while toxicity followed CTCAE v4.0.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/esophageal-cancer-outcomes-after-definitive-chemotherapy-with-intensity-modulated-proton-therapy/342791/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/esophageal-cancer-outcomes-after-definitive-chemotherapy-with-intensity-modulated-proton-therapy/342791.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What patient population and treatment approach were analyzed?","Question",{"text":112,"@type":113},"The study retrospectively evaluated 34 patients with locally advanced esophageal cancer treated with IMPT alongside concurrent chemotherapy as definitive therapy at MD Anderson from 2011 to 2021.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were survival outcomes and toxicity measured?",{"text":117,"@type":113},"Survival endpoints were estimated using the Kaplan-Meier method, and toxicities were scored according to CTCAE version 4.0.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main survival and recurrence outcomes reported?",{"text":121,"@type":113},"At a median follow-up of 39 months, the 5-year overall survival was 41.1%, progression-free survival 34.6%, local regional recurrence-free survival 78.1%, and distant metastasis-free survival 65.0%.",{"name":123,"@type":110,"acceptedAnswer":124},"What major toxicity findings were observed after IMPT?",{"text":125,"@type":113},"Common acute toxicities included hematologic toxicity, esophagitis (including late-onset), fatigue, weight loss, and nausea (including late-onset). Grade 3 rates were 26.0% for hematologic toxicity, 18.0% for esophagitis, and 9.0% for nausea, with no grade ≥3 weight loss or radiation pneumonitis reported.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},342791,1790147723,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","International Journal of Particle Therapy 11 (2024) 100009  \nContents lists available at ScienceDirect  \nInternational Journal of Particle Therapy  \njournal [homepage:](homepage: www.sciencedirect.com/journal/ijpt)[ www.sciencedirect.com/journal/ijpt](homepage: www.sciencedirect.com/journal/ijpt)  \nEsophageal Cancer Outcomes After Definitive Chemotherapy With Intensity Modulated Proton Therapy  \nChike O. Abana (MD, PhD)1,\\#, Pim J. Damen (MD)2, Peter S. van Rossum (MD, PhD)3, Pablo Lopez Bravo (MD)1, Xiong Wei (MD)1, Julianne M. Pollard-Larkin (PhD)4, Paige L. Nitsch (MS)4, Mariela Blum Murphy (MD)5, Wayne L. Hofstetter (MD)6, Zhongxing Liao (MD)1, Steven H. Lin (MD, PhD)1,⁎  \n1 Department of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \n2 Department of Radiation Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands  \n3 Department of Radiation Oncology, Amsterdam University Medical Center, Amsterdam, the Netherlands  \n4 Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \n5 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \n6 Department of Thoracic & Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \nA R T I C L E I N F O  \nKeywords: Esophageal cancer IMPT  \nPencil beam proton therapy Passive scatter proton therapy  \nA B S T R A C T  \nPurpose: The effectiveness of intensity-modulated proton therapy (IMPT) for esophageal cancer treated with definitive concurrent chemoradiation therapy remains inadequately explored. We investigated long-term outcomes and toxicity experienced by patients who received IMPT as part of definitive esophageal cancer treatment. Patients and Methods: We retrospectively identified and analyzed 34 patients with locally advanced esophageal cancer who received IMPT with concurrent chemotherapy as a definitive treatment regimen at The University of Texas MD Anderson Cancer Center from 2011 to 2021. The median IMPT dose was 50.4 GyRBE in 28 fractions; concurrent chemotherapy consisted of fluorouracil and/or taxane and/or platinum. Survival outcomes were determined by the Kaplan-Meier method, and toxicity was scored according to the Common Terminology Criteria for Adverse Events version 4.0.  \nResults: The median age of all patients was 71.5 years. Most patients had stage III (cT3 cM0) adenocarcinoma of the lower esophagus. At a median follow-up time of 39 months, the 5-year overall survival rate was 41.1%; progression-free survival, 34.6%; local regional recurrence-free survival, 78.1%; and distant metastasis-free survival, 65.0%. Common acute chemoradiation therapy-related toxicities included hematologic toxicity, esophagitis (and late-onset), fatigue, weight loss, and nausea (and late-onset); grade 3 toxicity rates were 26.0% for hematologic, 18.0% for esophagitis and 9.0% for nausea. No patient had grade ≥3 wt loss or radiation pneumonitis, and no patients had pulmonary fibrosis or esophageal fistula. No grade ≥4 events were observed except for hematologic toxicity (lymphopenia) in 2 patients.  \nConclusion: Long-term survival and toxicity were excellent after IMPT for locally advanced esophageal cancer treated definitively with concurrent chemoradiation therapy. When available, IMPT should be offered to such patients to minimize treatment-related cardiopulmonary toxicity without sacrificing outcomes.  \nIntroduction  \nPhoton-based radiation therapy has had well-documented beneficial effects on survival for patients with esophageal cancer. Specifically, trimodality therapy in which neoadjuvant concurrent chemoradiation is  \nfollowed by esophagectomy has been shown to yield higher rates of pathologic complete response, negative margins, and better overall survival relative to surgery alone.1–4 Other studies of trimodality therapy versus definitive concurrent chemo","cbCaiu68GA4rfPje","https://ap.wps.com/l/cbCaiu68GA4rfPje","pdf",610778,"English","# Abstract\n# Introduction\n## Photon-based radiation therapy in esophageal cancer\n## Rationale for proton beam therapy and IMPT\n# Patients and Methods\n# Results\n# Conclusion","[{\"question\":\"What patient population and treatment approach were analyzed?\",\"answer\":\"The study retrospectively evaluated 34 patients with locally advanced esophageal cancer treated with IMPT alongside concurrent chemotherapy as definitive therapy at MD Anderson from 2011 to 2021.\"},{\"question\":\"How were survival outcomes and toxicity measured?\",\"answer\":\"Survival endpoints were estimated using the Kaplan-Meier method, and toxicities were scored according to CTCAE version 4.0.\"},{\"question\":\"What were the main survival and recurrence outcomes reported?\",\"answer\":\"At a median follow-up of 39 months, the 5-year overall survival was 41.1%, progression-free survival 34.6%, local regional recurrence-free survival 78.1%, and distant metastasis-free survival 65.0%.\"},{\"question\":\"What major toxicity findings were observed after IMPT?\",\"answer\":\"Common acute toxicities included hematologic toxicity, esophagitis (including late-onset), fatigue, weight loss, and nausea (including late-onset). Grade 3 rates were 26.0% for hematologic toxicity, 18.0% for esophagitis, and 9.0% for nausea, with no grade ≥3 weight loss or radiation pneumonitis reported.\"}]","Esophageal Cancer Outcomes After Definitive Chemotherapy With Intensity Modulated Proton Therapy | PDF",1790048253,13,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eff2968245fec5d39eac65ef5542cf32.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8fc18a8f4921949da1c8e3c32c6f992.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5181ded620074bfcc17944a84520f3e.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42f5f6352d825dc5c42bdc77261a03c3.webp",980,1306]